DAM
SEEL

DLD Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

DLD Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$41K – 235
2021
Q4 		$41K Hold
7
– – ﹤0.01% 171
2021
Q3 		$60K Buy
+7
New +$60.2K ﹤0.01% 130

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

DLD Asset Management's SEEL Position: Q1 2022 in Review

DLD Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022, closing a stake of 7 shares — an estimated $41K sold.

DLD Asset Management first reported a position in SEEL in Q3 2021 and held it in 2 quarters. The position peaked at $60K in Q3 2021. 77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

  • DLD Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • DLD Asset Management sold 7 Seelos Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $41K.
  • DLD Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • DLD Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $60K in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on DLD Asset Management's 13F filing for Q1 2022, filed 13 May 2022.